A vs DHR vs RVTY Stock Comparison

Agilent Technologies, Danaher and Revvity Prices as of Oct 26, 2026 Peers: Industry group
A Agilent Technologies, Inc.
$175.96 +1.8% 1M +18.9% 1Y
Market cap
$50.15B
P/E
34.8x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
8 wins
DHR Danaher Corp /De/
$232.95 +3.7% 1M +4.5% 1Y
Market cap
$163.62B
P/E
40.9x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
RVTY Revvity, Inc.
$160.32 +6.1% 1M +62.1% 1Y
Market cap
$18.07B
P/E
76.0x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win

Head to Head

12 decided of 12

Agilent Technologies leads on 8 of the 12 questions below (Agilent Technologies 8, Danaher 3, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADHRRVTYLeader
Larger companyMarket capitalisation $50.15B $163.62B $18.07B DHR
Cheaper on earningsLower P/E, profitable companies only 34.8x 40.9x 76.0x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.9x 25.6x 31.4x DHR
Faster revenue growthRevenue growth, trailing twelve months +8.6% +4.6% +4.1% A
More profitableNet margin, trailing twelve months 19.5% 15.9% 8.2% A
Better return on capitalReturn on invested capital 13.1% 5.7% 3.1% A
Less leveragedLower net debt / EBITDA 1.1x 2.9x 2.8x A
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% A
Better 1-year returnPrice return, last 12 months +18.9% +4.5% +62.1% RVTY
Better 5-year returnAnnualised price return, 5 years +2.5%/yr -5.3%/yr -1.6%/yr A
Less volatileAnnualised volatility, 1 year 32.4% 30.7% 39.9% DHR
Higher overall scoreMean of the five percentile scores vs peers 62/100 59/100 58/100 A

Percentile Scorecard

ADHRRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADHRRVTY
Valuation 58 #97 of 228 67 #75 of 228 68 #73 of 228
Growth 36 #141 of 221 21 #176 of 221 27 #161 of 221
Profitability 91 #20 of 208 88 #26 of 208 79 #45 of 208
Financial Health 55 #108 of 239 46 #130 of 239 47 #128 of 239
Shareholder Returns 71 #40 of 137 76 #34 of 137 69 #43 of 137
Overall 62 59 58
  • A ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADHRRVTYSPY
1 month +1.8%+3.7%+6.1% -0.8%
3 months +27.6%+18.5%+48.4% +3.5%
6 months +52.2%+29.0%+84.7% +7.0%
Year to date +29.3%+1.8%+65.7% +12.2%
1 year +18.9%+4.5%+62.1% +13.0%
3 years +71.2%+24.0%+63.8% +86.3%
3 years, per year +19.6%+7.4%+17.9% +23.1%
5 years +13.3%-23.7%-7.8% +68.6%
5 years, per year +2.5%-5.3%-1.6% +11.0%
10 years +305.7%+199.7%+216.8% +258.0%
10 years, per year +15.0%+11.6%+12.2% +13.6%

Risk

MeasureADHRRVTYSPY
Volatility, 1Y 32.4%30.7%39.9% 12.7%
Downside volatility, 1Y 27.5%31.8%35.7% 12.7%
Beta vs S&P 500, 1Y 0.880.451.22 1.00
Return / volatility, 1Y 0.580.151.56 1.02
Max drawdown, 5Y -39.6%-50.8%-59.2% -25.4%
From 52-week high -1.0%-3.8%0.0% -1.8%
52-week high $177.72$242.05$160.32 $779.14
52-week low $110.24$161.91$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADHRRVTY
P/E now vs peer median 34.5xmedian 30.6x 41.0xmedian 30.6x 75.3xmedian 30.6x
P/S now vs peer median 6.7xmedian 3.0x 6.5xmedian 3.0x 6.1xmedian 3.0x
EV/EBITDA now vs peer median 27.1xmedian 17.5x 24.3xmedian 17.5x 25.9xmedian 17.5x
P/FCF now vs peer median 39.2xmedian 23.3x 30.0xmedian 23.3x 31.4xmedian 23.3x
P/B now vs peer median 6.7xmedian 2.4x 3.1xmedian 2.4x 2.5xmedian 2.4x
PEG now vs peer median 3.51median 0.87 -3.28median 0.87 -2.42median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADHRRVTY
Revenue $7.37B $25.11B $2.91B
Gross profit $3.97B $14.69B $1.60B
Operating income $1.64B $5.13B $358.85M
Net income $1.44B $4.00B $237.55M
Free cash flow $1.27B $5.47B $568.85M
R&D $485.00M $1.62B $215.83M
EPS (diluted) $5.09 $5.66 $2.13
Cash & equivalents $1.76B $4.35B $1.02B
Total debt $3.95B $26.56B $3.21B
Shares (diluted) 283.00M 707.60M 111.63M
Enterprise value $43.03B $147.42B $14.33B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADHRRVTY
P/E 34.5x 41.0x 75.3x
P/FCF 39.2x 30.0x 31.4x
P/Operating cash flow 30.8x 24.7x 28.0x
P/S 6.7x 6.5x 6.1x
P/B 6.7x 3.1x 2.5x
P/Tangible book 7.7x 5.2x 3.6x
EV/EBITDA 27.1x 24.3x 25.9x
EV/EBIT 31.6x 36.3x 55.9x
EV/Revenue 7.0x 7.4x 6.9x
EV/FCF 40.9x 34.0x 35.3x
EV/Operating cash flow 32.2x 28.0x 31.4x
PEG (3Y EPS CAGR) 3.51 -3.28 -2.42

Growth

14 metrics
MetricADHRRVTY
Revenue growth (1Y) 8.6% 4.6% 4.1%
Revenue CAGR (3Y) 1.8% -0.5% 0.9%
Gross profit growth (1Y) 11.2% 2.6% 2.3%
Gross profit CAGR (3Y) 3.7% -0.9% -0.4%
Operating income growth (1Y) 13.5% 16.1% -5.5%
Operating income CAGR (3Y) 5.1% -7.1% -3.7%
Net income growth (1Y) 18.0% 17.3% -16.7%
Net income CAGR (3Y) 8.3% -14.3% -33.8%
EPS growth (1Y) 18.9% 19.2% -12.3%
EPS CAGR (3Y) 9.8% -12.5% -31.2%
Operating cash flow growth (1Y) 7.6% 7.6% 6.2%
Operating cash flow CAGR (3Y) -1.9% -7.6% 86.9%
Free cash flow growth (1Y) 16.5% 12.4% 9.5%
Free cash flow CAGR (3Y) -3.7% -9.0% 64.8%

Profitability

14 metrics
MetricADHRRVTY
Gross margin 53.8% 58.5% 55.0%
EBITDA margin 25.9% 30.5% 26.6%
Operating margin 22.2% 20.4% 12.3%
Pretax margin 22.5% 19.0% 9.0%
Net margin 19.5% 15.9% 8.2%
FCF margin 17.2% 21.8% 19.5%
Operating cash flow margin 21.8% 26.4% 21.9%
Return on equity 19.9% 7.6% 3.3%
Return on assets 10.7% 4.5% 2.0%
Return on invested capital 13.1% 5.7% 3.1%
Return on capital employed 14.6% 6.4% 3.3%
Asset turnover 0.5x 0.3x 0.2x
Cash conversion (OCF / net income) 1.1x 1.7x 2.7x
Stock comp / revenue 1.8% 1.2% 0.8%

Financial Health

11 metrics
MetricADHRRVTY
Debt / assets 28.3% 28.8% 26.6%
Debt / equity 0.5x 0.5x 0.4x
Net debt / EBITDA 1.1x 2.9x 2.8x
Debt / FCF 3.1x 4.9x 5.6x
Liabilities / assets 47.3% 43.1% 40.0%
Equity / assets 52.7% 56.9% 60.0%
Interest coverage 15.5x 17.6x 3.7x
Current ratio 2.1x 1.7x 1.8x
Quick ratio 1.4x 1.0x 1.4x
Cash ratio 0.8x 0.5x 0.8x
Altman Z-score 5.82 3.72 3.38

Shareholder Returns

7 metrics
MetricADHRRVTY
Dividend yield 0.6% 0.7% 0.2%
Net buyback yield 0.6% 1.8% 2.6%
Shareholder yield 1.2% 2.4% 2.8%
Payout ratio (earnings) 19.9% – 13.4%
Payout ratio (FCF) 22.6% – 5.6%
Dividend growth (1Y) 2.1% – -6.3%
Dividend CAGR (3Y) 3.1% – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADHRRVTY
Forward P/E 26.9xFY2026 25.6xFY2026 31.4xFY2026
EPS, next fiscal year $6.54FY2026 $9.11FY2026 $5.10FY2026
EPS growth, next FY +17.0%FY2026 +16.8%FY2026 +0.8%FY2026
EPS growth, the year after +0.3% +8.0% +11.0%
Revenue, next fiscal year $7.87BFY2026 $27.01BFY2026 $2.98BFY2026
Revenue growth, next FY +15.3%FY2026 +9.9%FY2026 +4.0%FY2026
Revenue growth, the year after -5.6% -1.9% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADHRRVTY
Held by institutions 92.6% 81.9% 100.0%
Institutions holding 1,122 2,115 545
Change in shares held, QoQ +3.2% +1.1% -1.3%
Institutions buying 599 837 301
Institutions selling 350 1,015 161
Buyers to sellers 1.71 0.82 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADHRRVTY
A 1.00 0.60 0.64
DHR 0.60 1.00 0.51
RVTY 0.64 0.51 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, A, DHR and RVTY?

Danaher (DHR) is the largest by market capitalisation: Agilent Technologies (A) $50.15B, Danaher (DHR) $163.62B, Revvity (RVTY) $18.07B.

Which stock is cheaper, A, DHR and RVTY?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Agilent Technologies (A) 34.8x, Danaher (DHR) 40.9x, Revvity (RVTY) 76.0x). On next year's consensus earnings, Danaher (DHR) is cheapest (Agilent Technologies (A) 26.9x, Danaher (DHR) 25.6x, Revvity (RVTY) 31.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Agilent Technologies (A) +8.6%, Danaher (DHR) +4.6%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Agilent Technologies (A) 19.5%, Danaher (DHR) 15.9%, Revvity (RVTY) 8.2%). On return on invested capital, Agilent Technologies (A) leads (Agilent Technologies (A) 13.1%, Danaher (DHR) 5.7%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Agilent Technologies (A) +18.9%, Danaher (DHR) +4.5%, Revvity (RVTY) +62.1%. Over five years, Agilent Technologies (A) compounded fastest (Agilent Technologies (A) +2.5%/yr, Danaher (DHR) -5.3%/yr, Revvity (RVTY) -1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Agilent Technologies (A) 0.01%, Danaher (DHR) 0.00%, Revvity (RVTY) 0.00%. Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Agilent Technologies (A) 32.4%, Danaher (DHR) 30.7%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, A, DHR and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.